BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 17940386)

  • 21. [Complete response of advanced rectal cancer with combined therapy of S-1 + chemo-radiation plus FOLFIRI--a case report].
    Hata T; Kagawa Y; Ikeda K; Kato H; Takamoto K; Oshima N; Maeda S; Nomura M; Hayashi S; Sasaki T; Shimizu J; Kawanishi K; Fujita J; Akagi K; Tsukahara Y; Kitada M; Shimano T
    Gan To Kagaku Ryoho; 2008 Nov; 35(12):2177-9. PubMed ID: 19106562
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Report of a case effectively treated by appropriate therapy for severe anticipatory nausea and vomiting due to FOLFOX or FOLFIRI].
    Mori M; Kiba T; Oikawa M; Hokkoku K; Watanabe Y; Nakagawa T; Shintaku K; Yoshimitsu Y; Sakuma H; Ueda H; Nakai M
    Gan To Kagaku Ryoho; 2009 Feb; 36(2):325-7. PubMed ID: 19223757
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Simplified FOLFIRI in pre-treated patients with metastatic gastric cancer.
    Lorizzo K; Fazio N; Radice D; Boselli S; Ariu L; Zampino MG; Nolè F; Magni E; Ardito R; Minchella I; Rocca A; Di Meglio G; Squadroni M; de Braud F
    Cancer Chemother Pharmacol; 2009 Jul; 64(2):301-6. PubMed ID: 19034450
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [A case of liver metastasis of rectal cancer, refractory to previous chemotherapy(5-FU/LV, irinotecan, oxaliplatin) responding to bevacizumab combined with FOLFIRI chemotherapy].
    Nishigami K; Kawami H; Yamaguchi T; Yamaguchi K; Kato S
    Gan To Kagaku Ryoho; 2009 Oct; 36(10):1765-8. PubMed ID: 19838045
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Retrospective analysis of tegafur/uracil (UFT) plus oral leucovorin (LV) regimen in patients with advanced colorectal cancer].
    Sato Y; Inaba Y; Yamaura H; Shimamoto H; Nishiofuku H; Oyama T; Kanemitsu Y; Sawaki A; Arai Y; Muro K
    Gan To Kagaku Ryoho; 2006 Jul; 33(7):887-90. PubMed ID: 16835473
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A Markov model assessing the effectiveness and cost-effectiveness of FOLFOX compared with FOLFIRI for the initial treatment of metastatic colorectal cancer.
    Tumeh JW; Shenoy PJ; Moore SG; Kauh J; Flowers C
    Am J Clin Oncol; 2009 Feb; 32(1):49-55. PubMed ID: 19194125
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [A case of recurrent rectal cancer with lymphangiosis carcinomatosa successfully treated with modified FOLFOX6 therapy].
    Furuta R; Ina K; Kataoka T; Nagao S; Kayukawa S; Mori F; Masaki A; Ando T; Goto H
    Gan To Kagaku Ryoho; 2008 May; 35(5):849-52. PubMed ID: 18487928
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Benefit of tegafur-uracil and leucovorin in chemoradiotherapy for rectal cancer.
    Ishihara S; Hayama T; Yamada H; Nozawa K; Matsuda K; Watanabe T
    Hepatogastroenterology; 2011; 58(107-108):756-62. PubMed ID: 21830385
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Long-term results of a phase II trial of high-dose radiotherapy (60 Gy) and UFT/l-leucovorin in patients with non-resectable locally advanced rectal cancer (LARC).
    Vestermark LW; Jacobsen A; Qvortrup C; Hansen F; Bisgaard C; Baatrup G; Rasmussen P; Pfeiffer P
    Acta Oncol; 2008; 47(3):428-33. PubMed ID: 18348002
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The combination of 5-FU, leucovorin and CPT-11 (FOLFIRI) prolongs survival through inhibition of metastasis in an orthotopic model of colon cancer.
    Ishihara Y; Matsunaga K; Iijima H; Hasegawa G; Suzuki T; Sato A; Kobayashi T; Yang M; Hoffman RM
    Anticancer Res; 2010 Feb; 30(2):403-8. PubMed ID: 20332446
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Development of taste disorders following FOLFOX-FOLFIRI therapy and its effects on the QOL of patients with colorectal cancer].
    Takimoto N; Sugawara S; Iida A; Sakakibara T; Mori K; Sugiura M; Yamamura K; Adachi M
    Gan To Kagaku Ryoho; 2009 Mar; 36(3):431-5. PubMed ID: 19295267
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Effective cetuximab monotherapy for a case of recurrence rectal cancer after multiple previous chemotherapy treatment (FOLFOX, FOLFIRI)].
    Tomita M; Kuboi K; Kameyama N; Mitsuhashi H; Matsumoto N; Hasegawa Y; Sekimoto Y
    Gan To Kagaku Ryoho; 2011 Jan; 38(1):121-4. PubMed ID: 21368472
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A pilot study of oxaliplatin, fluorouracil and folinic acid (FOLFOX-6) as first-line chemotherapy in advanced or recurrent gastric cancer.
    Luo HY; Xu RH; Zhang L; Li YH; Shi YX; Lin TY; Han B; Wang F; Qiu MZ; He YJ; Guan ZZ
    Chemotherapy; 2008; 54(3):228-35. PubMed ID: 18560231
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Huge unresectable multiple hepatic metastases of rectum cancer responding to combined therapy with FOLFIRI +bevacizumab - a case report].
    Tagami Y; Ogata S; Katakawa M; Bando Y
    Gan To Kagaku Ryoho; 2012 Feb; 39(2):317-9. PubMed ID: 22333652
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Desensitization to oxaliplatin with two stages of premedication in a patient with metastatic rectal cancer.
    Nozawa H; Muto Y; Yamada Y
    Clin Ther; 2008 Jun; 30(6):1160-5. PubMed ID: 18640472
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [FOLFIRI with bevacizumab chemotherapy for a patient with recurrence of rectal cancer under haemodialysis for chronic renal failure].
    Hoshino H; Ishii Y; Hasegawa H; Endo T; Ochiai H; Hoshino Y; Matsunaga A; Shigeta K; Seo Y; Hoshino G; Kitagawa Y
    Gan To Kagaku Ryoho; 2012 Jun; 39(6):983-6. PubMed ID: 22705698
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Hepatic arterial infusion combined with oral UFT/UZEL systemic chemotherapy for unresectable liver metastasis of colorectal cancer.
    Tsutsumi S; Yamaguchi S; Tsuboi K; Fukasawa T; Tabe Y; Asao T; Kuwano H
    Hepatogastroenterology; 2008; 55(85):1419-22. PubMed ID: 18795703
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Feasibility of peripheral vein during FOLFOX/FOLFIRI chemotherapy through peripheral venous system].
    Kimura T; Iwase K; Aono T; Nakai S; Fujii M; Nishikawa K; Matsuda C; Shimada K; Hirota M; Nasu S; Wada D; Hasegawa J; Tanaka Y
    Gan To Kagaku Ryoho; 2008 Nov; 35(11):1889-94. PubMed ID: 19011337
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A FOLFIRI-induced complete tumor response in a patient with FOLFOX-refractory metastatic duodenal adenocarcinoma.
    Catania C; Pelosi G; Fazio N; Biffi R; Spitaleri G; Noberasco C; Zampino MG; Maggioni A; Trifirò G; Toffalorio F; Vigna PD; De Braud F; De Pas T
    Acta Oncol; 2010; 49(1):120-1. PubMed ID: 20100147
    [No Abstract]   [Full Text] [Related]  

  • 40. Treatment outcomes of oxaliplatin, 5-FU, and leucovorin as salvage therapy for patients with advanced or metastatic gastric cancer: a retrospective analysis.
    Seo HY; Kim DS; Choi YS; Sung HJ; Park KH; Choi IK; Kim SJ; Oh SC; Seo JH; Choi CW; Kim BS; Shin SW; Kim YH; Kim JS
    Cancer Chemother Pharmacol; 2009 Feb; 63(3):433-9. PubMed ID: 18398608
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.